Monday , December 18 2017
Home / Letter From The Editor / Editor’s Note, GLP-1 Agonist August 2014 Special Edition

Editor’s Note, GLP-1 Agonist August 2014 Special Edition

It is always interesting when two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. Our own advisory board endocrinologist, Stanley Schwartz, is a good example of that. Recently I had the opportunity to review a conversation that John E. Anderson, MD, and Vivian Fonseca, MD, had about the use of incretin mimetics with insulin and found it very interesting.